Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kyverna Therapeutics, Inc. ( (KYTX) ) just unveiled an announcement.
On October 29, 2025, Kyverna Therapeutics announced positive interim data from its Phase 2 KYSA-6 trial of KYV-101 for generalized myasthenia gravis (gMG). The trial showed that 100% of patients achieved clinically meaningful responses with significant reductions in MG-ADL and QMG scores, and KYV-101 was well-tolerated with no high-grade adverse events. These results reinforce the potential of KYV-101 to deliver durable remission with a single dose, setting a new clinical standard in gMG treatment and supporting the design of the upcoming Phase 3 trial.
The most recent analyst rating on (KYTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.
Spark’s Take on KYTX Stock
According to Spark, TipRanks’ AI Analyst, KYTX is a Underperform.
Kyverna Therapeutics, Inc. faces significant financial challenges, with consistent losses and zero revenue. The company’s technical indicators and valuation metrics reflect ongoing operational and financial difficulties. Key risks include negative profitability and weak market momentum, which significantly impact the stock’s performance.
To see Spark’s full report on KYTX stock, click here.
More about Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The company’s lead product, KYV-101, is a CAR T-cell therapy under investigation for B-cell-driven autoimmune diseases, aiming to achieve durable, drug-free remission.
Average Trading Volume: 510,339
Technical Sentiment Signal: Strong Buy
Current Market Cap: $329.1M
Find detailed analytics on KYTX stock on TipRanks’ Stock Analysis page.